NPNikiforita Poulakaki

Nikiforita Poulakaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nikiforita Poulakaki has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Constantine Gennatas

    Oncology Clinic, Department of Surgery, Areteion Hospital, University of Athens, Greece

    2 shared publications
  • Despina Mouratidou

    2 shared publications
  • Georgios-Marios Makris

    Department of Obstetrics and Gynecology, Rea Maternity Hospital, Athens, Greece; †Department of Breast Surgery, Euroclinic of Athens, Athens, Greece; ‡Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

    2 shared publications
  • John Psychogios

    2 shared publications
  • Nikolaos Tsavaris

    2 shared publications
  • Theodoros N. Sergentanis

    Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

    2 shared publications

Latest Publications

  • Vulvar, Perianal and Perineal Cancer After Hidradenitis Suppurativa: A Systematic Review and Pooled Analysis

    by Georgios-Marios Makris, Nikiforita Poulakaki, Aristea-Maria Papanota, Evgenia Kotsifa, Theodoros N. Sergentanis, Theodora Psaltopoulou

    BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease that frequently involves the perineal and perianal regions. The association between HS and malignant transformation is a rare but under recognized phenomenon. OBJECTIVE: This systematic review aims to summarize all available cases of vulvar and perianal/perineal cancer emerging in patients with HS, describing clinical and therapeutic particularities of these coexisting conditions in female patients. MATERIALS AND METHODS: This systematic review and pooled analysis was performed in accordance with the PRISMA guidelines; end-of-search date was June 15, 2015. RESULTS: A total of 13 eligible articles were identified; 7 cases of vulvar cancer and 6 cases of perineal/perianal carcinomas in patients with HS were noted. A majority of published cases pertained to rather advanced carcinomas; only occasionally early stage carcinomas were identified. The optimal modifications in the treatment scheme of vulvar, perianal, and perineal cancer in patients with HS have not been established; detailed reporting of recurrence- and survival-related aspects is advised. CONCLUSION: Vulvar, perianal, and perineal cancer represent a rare but serious complication of HS.


  • Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?

    by Nikiforita Poulakaki, Georgios-Marios Makris, Marco-Johannes Battista, Daniel Böhm, Kalliopi Petraki, Dimitrios Bafaloukos, Theodoros N. Sergentanis, Charalampos Siristatidis, Charalampos Chrelias, Nikolaos Papantoniou


  • Open Access

    The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients

    by Anna Koumarianou, Maria-Ioanna Christodoulou, Pavlos Patapis, Iordanis Papadopoulos, Elissavet Liakata, Athina Giagini, Anastasia Stavropoulou, Nikiforita Poulakaki, Nikolaos Tountas, Nikolaos Xiros, et al.

    The host’s immune system is crucially involved in cancer development and progression. The ratio of regulatory to effector T-cells, as well as the interplay of T-cells with therapeutic agents, impact on cancer prognosis. The current study aimed to comparatively investigate the effect of metronomic and standard chemotherapy on the number and functionality of peripheral regulatory and effector T-cells in cancer patients.


    • 1 January 2014
      • Vol. 35  (6) , 635-40

    Female sexuality after female cancer treatment: a clinical issue.

    by D Vaidakis, T Panoskaltsis, N Poulakaki, A Kouloura, D Kassanos, G Papadimitriou, E Salamalekis

    The aim of the present study was to record how the treatment of female cancer may affect sexuality and interpersonal relations in the couple. From September 2008 until February 2012, the authors prospectively studied 67 patients with breast cancer (Group A) and 43 with gynecological cancers (Group B). As control groups 33 patients with benign breast and 30 patients with benign gynecological lesions (group 0a and 0b respectively) were used. Sexuality and interpersonal relations were evaluated by a questionnaire. The authors also evaluated interpersonal relations focusing on sexual function at the time of diagnosis and a year after the initial treatment for cancer. A significant reduction of the "sexual desire", "sexual Arousal", and "orgasm" dimension was found in both cancer groups, in contrast to the control group, revealing no significant change. The "sexual enjoyment" scale was significantly decreased in gynecological cancer group but not in breast cancer group. While the score on the "relationship quality" dimension significantly increased in both cancer groups. In all groups, there was a significantly positive correlation between sexual function and enjoyment; on the contrary, there was a significantly negative correlation between relationship quality and sexual function and enjoyment. Sexual dysfunctions is a clinical problem which should be evidenced at the beginning of therapy, from the oncologists in order to provide integrated treatment to their patients.


    • 3 June 2006
      • Vol. 26, 549-52

    Gemcitabine in combination with vinorelbine for heavily pretreated advanced breast cancer.

    by Constantine Gennatas, Vasiliki Michalaki, Despina Mouratidou, Nikolaos Tsavaris, Charalambos Andreadis, John Psychogios, Nikiforita Poulakaki

    To evaluate the activity and toxicity of gemcitabine and vinorelbine in patients with metastatic breast cancer (MBC), previously treated with anthracyclines alone or with taxanes. A total of 86 pretreated patients with MBC (median age 62 years), entered the study. Thirty-six patients had been pretreated with anthracyclines and 8 were resistant. The combination of gemcitabine (1000 mg/m2) and vinorelbine (25 mg/m2) was administered on days 1 and 8 every 3 weeks, for a total of 6 cycles. A total of 344 cycles of chemotherapy were administered (median 4 cycles per patient). Partial responses were observed in 31 patients (36.0%; 95% CI: 23-56). The median duration of response was 7 months (range 3-11 months) and the median overall survival was 14 months (range 6-21). The scheme was well tolerated. The combination of vinorelbine and gemcitabine is an active scheme in pretreated MBC, demonstrating an acceptable toxicity profile, and may well represent a valuable therapeutic choice after anthracycline/taxane regimens.


  • Third-Line Hormonal Treatment with Exemestane in Postmenopausal Patients with Advanced Breast Cancer Progressing on Letrozole or Anastrozole. A Phase II Trial Conducted by the Hellenic Group of Oncology (HELGO)

    by Constantine Gennatas, Vasiliki Michalaki, Eleni Carvounis, John Psychogios, Nikiforita Poulakaki, George Katsiamis, Dionysios Voros, Vasilis Kouloulias, Despina Mouratidou, Nikolaos Tsavaris

    Aims and Background: The understanding of hormonal therapies in postmenopausal women with metastatic breast cancer has advanced greatly in the past several decades. With the introduction of orally active, potent and selective third-generation aromatase inhibitors (anastrozole, letrozole and exemestane), approaches to the treatment of hormone-sensitive advanced breast cancer are undergoing reevaluation. For treatment of advanced or metastatic disease that has progressed on tamoxifen, all three agents are active. The purpose of the study was to assess the antitumor efficacy and tolerance of exemestane administered as third-line hormonal therapy to postmenopausal women with metastatic breast cancer refractory to letrozole and anastrozole. Study design: Sixty postmenopausal women with stage IV hormone receptor-positive carcinoma of the breast were enrolled in the study. All patients had received two prior hormonal manipulations and had measurable or assessable disease. All adverse events were monitored. Results: Objective tumor response was achieved in 12 (20%) patients (95% CI, 9.6-30.4). The overall clinical benefit was 38.3% (95% CI, 21.2-49.3), and the median duration of objective tumor response was 20 months (range, 9-26). The median time to death was 17.4 months (95% CI, 16.14-18.66). Conclusions: Exemestane represents an active and well-tolerated treatment option in pretreated patients with advanced breast cancer who have received standard first- and second-line hormonal therapies. By extending the sequence of hormonal therapy, disease progression and the need for chemotherapy may be significantly delayed.


  • Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women

    by Kimon S Stamatelopoulos, John P Lekakis, Nikiforita A Poulakaki, Christos M Papamichael, Kyriaki Venetsanou, Konstantinos Aznaouridis, Athanasios D Protogerou, Theodoros G Papaioannou, Sanjay Kumar, Stamatios F Stamatelopoulos